NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,207.13 +444.10 (+2.50%) CRUDE OIL
78.95 -0.05 (-0.06%) GOLD FUTURES
2,311.50 +0.50 (+0.02%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,321.68 +2,020.93 (+4.46%)
Cytosorbents Corporation (CTSO)
After hours:
| Previous close | 0.8407 |
| Open | 0.8430 |
| Bid | 0.7875 x 100 |
| Ask | 0.8539 x 200 |
| Day's range | 0.7995 - 0.8761 |
| 52-week range | 0.7820 - 4.2900 |
| Volume | |
| Avg. volume | 100,367 |
| Market cap | 44.499M |
| Beta (5Y monthly) | 0.59 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings date | 09 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 3.70 |
GlobeNewswireCytoSorbents May 6, 2024 Virtual KOL and Analyst-Investor Day: STAR-T Pivotal Trial Topline Results & Real World Experience with Antithrombotic Drug Removal in Europe
PRINCETON, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it will host a virtual Key Opinion Leader and Analyst-Investor Day on Monday, May 6, 2024 from 11:30 AM to 1:30 PM ET. To register, click here. The program will cover the significant challenge of severe perio
- GlobeNewswire
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024. CytoSorbents’ management will host a live conference call and presentation webcast and a question and answer session starting at 4:30PM EDT the same day. Webcast D
- GlobeNewswire
STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation a
